Ezetimibe selectively inhibits the Niemann-Pick C1-like 1 (NPC1L1) protein, a sterol transporter located on the apical membrane of small intestinal enterocytes and, to a lesser extent, on hepatocyte canalicular membranes.¹ NPC1L1 mediates the absorption of both dietary and biliary cholesterol from the intestinal lumen into enterocytes. Ezetimibe localizes to the brush border of the small intestine and blocks NPC1L1-mediated cholesterol uptake — it does not inhibit triglyceride or fat-soluble vitamin absorption, which distinguishes it from bile acid sequestrants.¹ Reduced intestinal cholesterol delivery to the liver decreases hepatocellular cholesterol content, which — via the same sterol regulatory element-binding protein (SREBP)-2 pathway activated by statins — upregulates hepatic LDL receptor (LDLR) expression and accelerates plasma low-density lipoprotein cholesterol (LDL-C) clearance. This mechanism is distinct from and complementary to statin-mediated inhibition of hepatic cholesterol synthesis: ezetimibe reduces cholesterol input from the intestine, while statins reduce de novo hepatic synthesis. Their combination therefore produces additive LDL-C lowering that substantially exceeds either agent alone.¹

Ezetimibe is administered orally at a fixed dose of 10 mg once daily, independent of meals and without dose titration. It undergoes extensive glucuronide conjugation in the intestinal wall and liver, with the glucuronide metabolite (ezetimibe-glucuronide) being pharmacologically active and undergoing enterohepatic recirculation — a pharmacokinetic feature that prolongs its effective exposure and enables once-daily dosing.¹ Ezetimibe is minimally metabolized by cytochrome P450 (CYP450) enzymes and carries an extremely low drug-drug interaction potential. No dose adjustment is required for renal impairment. In severe hepatic impairment (Child-Pugh C), ezetimibe use is not recommended due to substantially increased plasma exposure from impaired glucuronidation. It is not absorbed systemically in significant quantities, minimizing systemic adverse effects.

Ezetimibe monotherapy reduces LDL-C by approximately 18–20% from baseline.¹ When added to statin therapy, it provides an additional 18–25% LDL-C reduction on top of whatever reduction the statin has already achieved — the combination of statin plus ezetimibe reduces LDL-C by approximately 60–65% from the untreated baseline, which is greater than any single statin dose can achieve. In absolute terms, for a patient with baseline LDL-C of 130 mg/dL on maximally tolerated rosuvastatin 40 mg achieving 58 mg/dL, adding ezetimibe would be expected to reduce LDL-C by approximately 18–20% further — to approximately 46–48 mg/dL. This additional reduction carries meaningful clinical benefit in high-risk patients, as demonstrated in Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT).

The Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT, 2015) was the landmark study establishing that non-statin LDL-C lowering — specifically via ezetimibe — reduces cardiovascular events.² IMPROVE-IT enrolled 18,144 patients stabilized after acute coronary syndrome (ACS) and randomized them to simvastatin 40 mg plus ezetimibe 10 mg versus simvastatin 40 mg plus placebo. The primary endpoint — a composite of cardiovascular death, non-fatal MI, unstable angina requiring hospitalization, coronary revascularization, and non-fatal stroke — was reduced by 6.4% relative risk reduction (34.7% vs. 32.7% absolute event rates) over a median 6 years in favor of combination therapy, with a mean achieved LDL-C of 53.7 mg/dL vs. 69.5 mg/dL.²

While the absolute risk reduction was modest, IMPROVE-IT was profoundly important for two reasons: it confirmed for the first time that non-statin LDL-C lowering reduces cardiovascular events — validating the "lower is better" principle beyond the statin class — and it demonstrated that achieving very low LDL-C levels (<53 mg/dL) is safe, with no evidence of a J-curve or increased harm at low LDL-C values. Subgroup analyses showed greater absolute benefit in higher-risk subgroups — diabetic patients, the elderly, and those with prior atherosclerotic cardiovascular disease (ASCVD) events — consistent with the risk-based benefit scaling framework.²

Ezetimibe has an excellent tolerability profile. The most commonly reported adverse effects — gastrointestinal discomfort, headache, and myalgia — occur at rates not significantly different from placebo in randomized trials.¹ Unlike statins, ezetimibe is not associated with hepatotoxicity, new-onset diabetes, or drug-drug interactions via CYP450. There is no evidence of cancer risk, cognitive impairment, or hormonal effects. Rare case reports of myopathy have appeared, but causality is not established. The safety data from IMPROVE-IT (median 6 years, 18,144 patients) provide robust long-term reassurance. The favorable safety profile, once-daily fixed dosing, and low cost (ezetimibe is now generic in most markets) make it the logical first add-on agent to maximally tolerated statin therapy in patients not at LDL-C target.

Inclisiran (Leqvio) represents a mechanistically distinct approach to PCSK9 inhibition. Rather than blocking PCSK9 protein in the extracellular space with an antibody, inclisiran is a small interfering RNA (siRNA) molecule that is delivered to hepatocytes via conjugation to triantennary N-acetylgalactosamine (GalNAc), which binds the asialoglycoprotein receptor on hepatocytes and enables selective hepatic uptake.⁶ Once inside the hepatocyte, inclisiran is loaded into the RNA-induced silencing complex (RISC), which cleaves PCSK9 mRNA with high specificity, preventing translation of PCSK9 protein. Because RISC is catalytic and stable within the hepatocyte, a single dose of inclisiran suppresses PCSK9 mRNA for months — the duration of effect is governed by RISC half-life rather than drug plasma half-life. This accounts for inclisiran's extraordinary dosing schedule: after an initial dose on day 1, a second dose is given at 3 months, and subsequent doses are given every 6 months.⁶ The plasma half-life of inclisiran itself is approximately 9 hours, but intrahepatic RISC activity persists for months after clearance of plasma drug.

Inclisiran reduces LDL-C by approximately 50–55% from baseline when added to maximally tolerated statin therapy — comparable to the monoclonal antibody PCSK9 inhibitors.⁶ The ORION phase 3 inclisiran trial program (ORION) program — a series of phase 3 trials (ORION-9, ORION-10, ORION-11) — enrolled patients with heterozygous familial hypercholesterolemia (FH) (ORION-9), atherosclerotic cardiovascular disease (ASCVD) or ASCVD risk equivalents (ORION-10 and ORION-11) and demonstrated consistent, durable low-density lipoprotein cholesterol (LDL-C) lowering of 48–52% from baseline on background statin with ezetimibe.⁶ LDL-C lowering is stable between doses, without the trough-to-peak fluctuation seen with biweekly monoclonal antibodies — a function of the continuous intrahepatic suppression of PCSK9 synthesis. FDA approval was granted in 2021 for adults with established cardiovascular disease or primary hyperlipidemia (heterozygous FH or clinical ASCVD) as an adjunct to maximally tolerated statin therapy.⁶

At the time of FDA approval, inclisiran was approved based on LDL-C reduction rather than demonstrated cardiovascular event reduction — a source of ongoing payer and clinical debate. The pivotal cardiovascular outcomes trial, ORION-4, enrolled approximately 15,000 patients with established ASCVD and is ongoing, with results anticipated in 2026. Early data from VICTORION-2P (a 3,000-patient trial in patients with prior MI or stroke) reported in 2024 showed a nominally positive trend in the primary composite but did not achieve statistical significance at interim analysis, likely due to insufficient follow-up duration. The cardiology community broadly anticipates that ORION-4 will confirm event reduction consistent with the LDL-C lowering magnitude, given the mechanistic and LDL-C outcome equivalence with evolocumab and alirocumab, but formal proof of cardiovascular event reduction from inclisiran remains pending as of this writing.⁶

Inclisiran is administered as a 284 mg subcutaneous injection at day 1, month 3, and then every 6 months — a total of 3 injections per year. This twice-yearly healthcare provider-administered dosing model is a fundamental differentiator from the biweekly or monthly self-injection regimens of the monoclonal antibodies and directly addresses adherence as a barrier to sustained LDL-C control.⁶ No dose adjustment is required for renal impairment. Mild-to-moderate hepatic impairment does not significantly affect pharmacokinetics; severe hepatic impairment has not been adequately studied. Adverse effects are minimal: injection site reactions (erythema, pain, rash) occur in approximately 8% of patients versus 2% for placebo and are generally mild and transient. No cytochrome P450 (CYP) interactions, no myopathy risk, no hepatotoxicity, no diabetogenic effect, and no immune reactions have been identified at clinically meaningful rates.⁶

All three approved proprotein convertase subtilisin/kexin type 9 inhibitors achieve comparable low-density lipoprotein cholesterol lowering of approximately 50 to 60 percent from baseline on background statin therapy, and all have demonstrated freedom from harm at very low achieved low-density lipoprotein cholesterol levels — a critical reassurance given historical concerns about the safety of very low low-density lipoprotein cholesterol. The distinctions that matter clinically are mechanism, dosing schedule, cardiovascular outcomes evidence, and the practical considerations that determine real-world use.

Evolocumab (Repatha) is a fully human immunoglobulin G subclass 2 monoclonal antibody administered subcutaneously at 140 milligrams every 2 weeks or 420 milligrams monthly. It is FDA-approved for adults with heterozygous or homozygous familial hypercholesterolemia and for adults with established atherosclerotic cardiovascular disease requiring additional low-density lipoprotein cholesterol lowering. The Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk trial enrolled 27,564 patients with established atherosclerotic cardiovascular disease on background statin and demonstrated a 15 percent relative risk reduction in the primary composite endpoint and a 20 percent reduction in the secondary composite of cardiovascular death, myocardial infarction, or stroke over a median of 2.2 years. The open-label extension with up to 5 years of follow-up demonstrated sustained safety and ongoing event reduction. Evolocumab is also approved for homozygous familial hypercholesterolemia in patients aged 13 and older, achieving approximately 30 percent low-density lipoprotein cholesterol reduction in this population where the effect is attenuated by the near-absence of functional low-density lipoprotein receptors.

Alirocumab (Praluent) is a fully human immunoglobulin G subclass 1 monoclonal antibody administered subcutaneously at 75 milligrams every 2 weeks (with option to increase to 150 milligrams every 2 weeks if response is inadequate) or 300 milligrams every 4 weeks. It is FDA-approved for heterozygous familial hypercholesterolemia and established atherosclerotic cardiovascular disease with additional low-density lipoprotein cholesterol lowering needed. The ODYSSEY OUTCOMES trial enrolled 18,924 patients with recent acute coronary syndrome on maximally tolerated statin and demonstrated a 15 percent relative risk reduction in the primary endpoint (composite of coronary heart disease death, non-fatal myocardial infarction, fatal or non-fatal ischemic stroke, or unstable angina requiring hospitalization) and a nominally significant reduction in all-cause mortality — the first proprotein convertase subtilisin/kexin type 9 inhibitor to show an all-cause mortality signal, driven primarily by reduced cardiovascular mortality. The subgroup analysis of patients with baseline low-density lipoprotein cholesterol at or above 100 milligrams per deciliter showed particularly strong absolute risk reductions, supporting more aggressive use in the highest-risk post-acute coronary syndrome patients with elevated baseline lipids.

Inclisiran (Leqvio) is a small interfering ribonucleic acid agent administered subcutaneously at 284 milligrams on day 1, month 3, and then every 6 months — the twice-yearly healthcare-provider-administered schedule being its primary practical differentiator. Its mechanism operates upstream of the monoclonal antibodies: rather than blocking circulating proprotein convertase subtilisin/kexin type 9 protein, inclisiran suppresses hepatic proprotein convertase subtilisin/kexin type 9 messenger ribonucleic acid synthesis via the RNA-induced silencing complex, providing sustained intrahepatic suppression between doses. It is approved for heterozygous familial hypercholesterolemia and established atherosclerotic cardiovascular disease as an adjunct to maximally tolerated statin. As of this writing, the cardiovascular outcomes trial data (ORION-4) are awaited, distinguishing it from evolocumab and alirocumab whose event reduction is definitively established.

The practical selection framework between these agents reduces to four considerations. First, cardiovascular outcomes data — evolocumab and alirocumab have definitive outcomes evidence; inclisiran has low-density lipoprotein cholesterol lowering evidence with outcomes data pending. For patients where the prescribing decision hinges on demonstrated mortality reduction, the monoclonal antibodies currently have a stronger evidence base. Second, dosing frequency and administration model — inclisiran's twice-yearly healthcare-provider administration is superior for patients with adherence problems or injection anxiety; the biweekly/monthly self-injection schedule of the monoclonal antibodies requires patient engagement and technique. Third, speed of effect — the monoclonal antibodies achieve near-maximal low-density lipoprotein cholesterol lowering within 1 to 2 weeks of the first dose; inclisiran's effect builds over the first month after the day-1 dose, making the monoclonal antibodies preferable when urgent low-density lipoprotein cholesterol reduction is needed (early post-acute coronary syndrome, very high baseline low-density lipoprotein cholesterol).

Fourth, steady-state low-density lipoprotein cholesterol stability — inclisiran produces a more stable low-density lipoprotein cholesterol level between doses (less trough-to-peak variation) compared to the biweekly monoclonal antibodies, which may produce modest low-density lipoprotein cholesterol fluctuation between injections. This is unlikely to be clinically significant but may be relevant for patients with very low low-density lipoprotein cholesterol targets.

In the United States, all three proprotein convertase subtilisin/kexin type 9 inhibitors require prior authorization from commercial and government payers before prescribing, and prior authorization denial rates have historically been high — exceeding 50 percent in some health system analyses. Understanding the prior authorization requirements and the appeals process is a practical clinical skill that determines whether patients actually receive these drugs after a prescribing decision is made.

Standard prior authorization criteria across most payers include: (1) documented atherosclerotic cardiovascular disease or heterozygous or homozygous familial hypercholesterolemia diagnosis; (2) current use of maximally tolerated statin therapy — typically defined as atorvastatin 40 to 80 milligrams or rosuvastatin 20 to 40 milligrams, with documentation of statin intolerance if a lower-intensity statin is prescribed; (3) addition of ezetimibe if tolerated (some payers require a trial of statin plus ezetimibe before approving proprotein convertase subtilisin/kexin type 9 inhibitors — the step therapy or fail-first requirement); (4) low-density lipoprotein cholesterol above a threshold despite background therapy — typically above 70 milligrams per deciliter for very high risk and above 100 milligrams per deciliter for high risk, though this varies by payer; and (5) repeat documentation of elevated low-density lipoprotein cholesterol from two measurements taken at least 4 weeks apart in some cases.

The step therapy or fail-first requirement — mandating documented ezetimibe use before approving a proprotein convertase subtilisin/kexin type 9 inhibitor — is clinically appropriate for most patients given the cost and efficacy of ezetimibe, but creates barriers in specific high-risk clinical scenarios. In patients with very high baseline low-density lipoprotein cholesterol (above 190 milligrams per deciliter), recurrent atherosclerotic cardiovascular disease events, or recent acute coronary syndrome with persistently elevated low-density lipoprotein cholesterol despite maximally tolerated statin, the sequential add-on approach may introduce clinically unacceptable delays. In these situations, appeal letters documenting medical necessity — with citation of the specific guideline indication and the patient's cardiovascular risk profile — are often successful in obtaining coverage without completing the step therapy sequence.

Patient assistance programs are available from the manufacturers of evolocumab (Amgen), alirocumab (Sanofi/Regeneron), and inclisiran (Novartis) for patients with inadequate insurance coverage or who face high out-of-pocket costs. These programs can reduce or eliminate patient cost-sharing and are a practical option for uninsured or underinsured patients who meet the clinical criteria for proprotein convertase subtilisin/kexin type 9 inhibitor therapy.

Low-density lipoprotein cholesterol response to proprotein convertase subtilisin/kexin type 9 inhibitors should be assessed 4 to 12 weeks after initiation with a fasting lipid panel, consistent with the monitoring approach for any lipid-lowering therapy change. Dose adjustment is not available for evolocumab (140 milligrams every 2 weeks is the only approved dose for atherosclerotic cardiovascular disease; 420 milligrams monthly is an alternative). For alirocumab, dose escalation from 75 to 150 milligrams every 2 weeks is available if the low-density lipoprotein cholesterol response at 4 to 8 weeks is insufficient.

If low-density lipoprotein cholesterol falls well below target — particularly below 25 milligrams per deciliter — consideration should be given to de-escalating background statin or ezetimibe to achieve a target range rather than the lowest achievable level, as the long-term clinical safety of very low low-density lipoprotein cholesterol below 20 milligrams per deciliter remains an area of ongoing study. Current guideline bodies have not endorsed a lower low-density lipoprotein cholesterol safety floor, and existing evidence from Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk and ODYSSEY OUTCOMES does not suggest harm at levels as low as 10 to 15 milligrams per deciliter, but the absence of a demonstrated harm threshold should not be interpreted as evidence that lower is always better beyond the currently established cardiovascular targets.